For Black Diamond Therapeutics Inc. (BDTX), this quarter is shaping up to be an eventful period, with multiple clinical trial catalysts anticipated across its MasterKey portfolio.
The company's Masterkey therapy approach targets families of oncogenic mutations, enabling an expanded addressable patient population. Designed to be potent across broad mutation families, including drug-resistant variants, with brain-penetrant properties to treat CNS disease, while maintaining selectivity for better tolerability. In contrast, the traditional oncology approach focuses on targeting single mutations within specific tumor types, often limiting patient reach and making it more vulnerable to resistance.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com